555 related articles for article (PubMed ID: 34303267)
1. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
[TBL] [Abstract][Full Text] [Related]
2. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
3. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
5. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
6. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 May; 22(5):690-701. PubMed ID: 33798493
[TBL] [Abstract][Full Text] [Related]
7. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
Chung MJ; Kim YJ; Park JY; Bang S; Song SY; Chung JB; Park SW
Chemotherapy; 2011; 57(3):236-43. PubMed ID: 21597288
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK; Chon HJ; Cheon J; Lee MA; Im HS; Jang JS; Kim MH; Park S; Kang B; Hong M; Kim JW; Park HS; Kang MJ; Park YN; Choi HJ
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
[TBL] [Abstract][Full Text] [Related]
14. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T
Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Sym SJ; Hong J; Park J; Cho EK; Lee JH; Park YH; Lee WK; Chung M; Kim HS; Park SH; Shin DB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):481-8. PubMed ID: 23192279
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Moore M; Gill S; Asmis T; Berry S; Burkes R; Zbuk K; Alcindor T; Jeyakumar A; Chan T; Rao S; Spratlin J; Tang PA; Rothenstein J; Chan E; Bendell J; Kudrik F; Kauh J; Tang S; Gao L; Kambhampati SR; Nasroulah F; Yang L; Ramdas N; Binder P; Strevel E
Ann Oncol; 2016 Dec; 27(12):2216-2224. PubMed ID: 27733377
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK
Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
Belkouz A; de Vos-Geelen J; Mathôt RAA; Eskens FALM; van Gulik TM; van Oijen MGH; Punt CJA; Wilmink JW; Klümpen HJ
Br J Cancer; 2020 Mar; 122(5):634-639. PubMed ID: 31919404
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
